Wu Zhicai

The story of Abtech began in 2011. "In the first five years, we had already developed tens of thousands of research antibodies, focusing on the research market segment," Wu Zhicai recalled. The extensive library of research antibodies laid a solid technical foundation for the company, but the real leap occurred five years ago with a strategic upgrade—entering the high-tech barrier field of flow cytometry antibodies. The company globally launched a set of flow antibody products specifically designed for laboratory monkeys, precisely addressing a key pain point in preclinical drug development.

"Previously, human antibodies were used to 'cross-react' with monkeys, which was actually a makeshift solution," Wu Zhicai explained. After the launch of this innovative product, it not only quickly secured orders from leading domestic pharmaceutical companies but also attracted multiple international pharmaceutical firms to proactively purchase it, achieving a "reverse globalization" of high-end reagents.

However, Abtech's most distinctive advantage lies in its construction of a complete ecosystem. At the exhibition booth, Wu Zhicai pointed to their flow cytometer and said, "This is our flow cytometer product. Our initial idea was to create a complete solution from reagents to equipment."

He elaborated on the strategic logic behind this: the flow cytometer serves as a "traffic entry point." When the equipment forms a closed loop with self-developed flow antibodies, it creates a powerful innovation platform. "Once the entire solution is integrated, you gain greater space for innovation." For example, Abtech is collaborating with Tongji Hospital in Wuhan, leveraging its flow cytometry equipment and reagents to jointly develop China's own clinical standards for leukemia.

"Among domestic enterprises, very few can achieve a complete solution covering both equipment and reagents," Wu Zhicai admitted, acknowledging that this path is more challenging. However, this is precisely Abtech's resolute strategic choice, serving as its most distinctive hallmark and core competitive barrier.

If choosing the path of a complete "reagents + equipment" ecosystem reflects Abtech's strategic boldness, then its globally pioneering flow antibody products for laboratory monkeys represent the concentrated embodiment of its innovative capabilities under this strategy.

Any grand vision for innovation ultimately relies on robust product quality to be realized. For Abtech, which is committed to building an ecosystem, its confidence in achieving "reverse globalization" and gaining recognition from top-tier pharmaceutical companies stems precisely from this foundation.

"The technical barriers for flow cytometry antibodies are relatively high, and this demand represents a very large market within the pharmaceutical industry, one that has been largely dominated by imports," Wu Zhicai highlighted the market realities at the time. To break this monopoly, the only way was to compete head-on in quality.

Abtech's next-generation ABflo® recombinant rabbit monoclonal antibodies for flow cytometry surpass traditional hybridoma technology, excelling in specificity, affinity, and batch-to-batch consistency. From target screening and antibody design to expression purification and final application validation, strict industrial-grade quality control standards are enforced to ensure each antibody demonstrates exceptional reproducibility and signal-to-noise ratio. Additionally, Abtech conducts rigorous head-to-head data comparisons for every flow antibody.

This relentless focus on quality has yielded confident results. "Currently, about 40% of our products are better than imported ones, while tens of percent are on par with them. We have reached a state where we are essentially equal," Wu Zhicai stated. From the perspective of import substitution, Abtech's products now fully meet the standard of being "highly effective," not merely "usable."

As the conversation deepened, several other instruments on the display stand revealed Abtech's broader ambitions—automated Western Blot systems, multiplex protein analysis platforms for stem cells, the top-selling domestic brand SPR (surface plasmon resonance) instrument, and a droplet microfluidic analysis system rivaling U.S. giants… Almost every device has become a domestic leader in its respective niche.

"People are often surprised when they see such a comprehensive portfolio of solutions," Wu Zhicai remarked. "Previously, there was no brand positioned to systematically supply both high-end instruments and high-end reagents."

This highlights Abtech's ultimate market positioning: to become a "foundational supplier" for pharmaceutical R&D ecosystems. As Chinese pharmaceutical companies increasingly prioritize R&D investment, their demands for supply chain stability, cost control (Abtech's products are priced at about 60%-70% of imported equivalents), and technical support have grown. "We cannot rely entirely on imported products to support your R&D system," Wu Zhicai emphasized. He believes Abtech is striving to become the first domestic brand capable of systematically supporting the entire supply chain for pharmaceutical R&D.

As the interview concluded, reflecting on the era dominated by imported instruments and reagents took on a new meaning. Abtech's journey mirrors the broader transition of China's biopharmaceutical industry from import dependency to domestic innovation. By steadfastly pursuing the path of providing complete "high-end reagents and instruments" solutions, Abtech symbolizes how Chinese biotech companies are evolving from being mere participants in the supply chain to becoming definers of technical standards and pioneers of innovative pathways. As domestically developed platforms gradually become integral R&D infrastructure, China's drug innovation pipeline will gain a more solid, controllable, and sustainable foundation.